Francisco Trust, acting as both a 10% shareholder and a director within Dyadic International Inc. (NASDAQ:DYAI), has executed a series of divestments totaling approximately $124,957 in value. These transactions took place over a three-day window from July 22 to July 24, 2026, marking a notable shift in the trust's direct holdings.
The liquidation involved the sale of 38,016 shares on July 22, 2026, followed by 54,760 shares on July 23, 2026, and a final tranche of 2,616 shares on July 24, 2026. The execution prices for these shares ranged between $1.2131 and $1.3279 per share. The timing of these sales coincides with a period of significant price appreciation for Dyadic International. According to data from InvestingPro, the stock has delivered a 32% return over the past six months and recorded a 27% gain year-to-date. While InvestingPro highlights strong performance metrics over the last three months, a Fair Value analysis indicates the stock is currently trading at a slight premium, suggesting it may be marginally overvalued relative to intrinsic metrics.
Following the completion of these transactions, Francisco Trust maintains a direct stake of 3,280,272 shares in Dyadic International Inc. common stock. The regulatory filing documenting these movements was signed by Thomas Emalfarb, serving as the Trustee of Francisco Trust.
Concurrent with the insider activity, Dyadic International has reported substantial operational developments. For the first quarter of 2026, the company announced a 182% year-over-year revenue increase, reaching $1.1 million. Despite this revenue surge, the company's earnings per share (EPS) remained at a loss of $0.05, a figure that aligns with analyst expectations. The company has also advanced its technological capabilities, announcing the expansion of its bio-industrial pipeline with a new proprietary enzyme program focused on cellulose processing. This initiative follows the successful commercialization of its first proprietary bio-industrial enzyme product, EN3ZYME.
Further strengthening its intellectual property portfolio, Dyadic secured a patent from the Japan Patent Office for its Thermothelomyces heterothallica recombinant protein expression technology. This patent enhances the company's C1 and Dapibus production platforms. Additionally, shareholders recently approved the election of Seth J. Herbst, M.D., as a Class I director at the 2026 Annual Meeting, reflecting ongoing governance updates.
Market data reflects recent trading activity with the stock closing at $1.19, representing a decline of $0.02 or 1.65% on July 24. After-hours trading data indicates a neutral movement of 0.00% at 19:34:09. The stock's performance over various timeframes shows volatility, with the 1-day chart indicating a low of $1.11 and a high approaching $1.20.